Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3804 Phase 1 in Advanced Malignant Tumors
NCT04128085Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3804 in malignant solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
TQB3804
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04128085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128085.